Tumor Biology

, Volume 37, Issue 4, pp 5295–5303 | Cite as

The protective role of the −1306C>T functional polymorphism in matrix metalloproteinase-2 gene is associated with cervical cancer: implication of human papillomavirus infection

Original Article

Abstract

Cervical cancer is the major reproductive health problem among women caused by persistent infection of high-risk human papillomavirus (HR-HPV). Metalloproteinase-2 (MMP-2) is an endopeptidase highly expressed in cervical cancer; however, the genetic link between aberrant expression of MMP-2 and cervical carcinogenesis is not known. The genotypic distribution, expression pattern of MMP-2 and HPV infection, was analyzed in a total of 300 fresh surgically resected cervical tissue biopsies. The MMP-2 C1306T (rs243865) promoter polymorphism dominant model (CC v/s CT + CT + TT) revealed that the CC genotype had a 4.33-fold significant increased risk for development of cervical cancer (OR = 4.33; 95 % CI = 2.36–4.02, p = 0.0001) compared to those with variant genotypes (−1306 CT + TT). The C allele was associated with 3-fold significant increased risk (OR = 2.95; 95 % CI = 1.90–4.60, p = 0.0002) compared to T allele. Interestingly, a significant correlation was found between high expression of MMP-2 protein and CC genotype in cancer patients (p = 0.001) compared to normal controls (p = 0.012). Further analysis showed that the risk of cancer was extremely pronounced in HPV positive patients (OR = 9.33; 95 % CI = 2.88–30.20, p = 0.0001) compared to HPV negative ones, implicating the possible interaction between −1306CC genotype and HPV infection in increasing the cancer risk (p = 0.0001). The leads from the present study suggest the protective role of gene variant −1306C>T at the promoter region of the MMP-2 against HPV-mediated cervical cancer. These findings substantiate the functional role of MMP-2 C1306T polymorphism in a significant downregulation of MMP-2 protein in women with variant genotype (CT/TT) compared to the normal wild CC genotype.

Keywords

Cervical cancer MMP-2 HPV Promoter polymorphism 

Notes

Acknowledgments

We acknowledge the funding by Department of Biotechnology (DBT), Govt. of India. We highly appreciate the help done by the staff and patients of Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Authors’ contributions

NS conceived the study, collected the samples, and carried out all the experiments and primary manuscript writing. SH participated in data analysis and critically reviewed the manuscript. US participated in DNA extraction and PCR VS senior Gynaecologist provided clinical samples and critical revision of manuscript. RN senior pathologist did the histopathological analysis of the cervical specimens. MB contributed to critical revision of the manuscript. RCS senior scientist supervised and guaranteed the work. All authors read and approved the final manuscript.

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Deodhar K et al. Prevalence of human papillomavirus types in cervical lesions from women in rural Western India. J Med Virol. 2012;84(7):1054–60.CrossRefPubMedGoogle Scholar
  2. 2.
    Agarwal S et al. Profile of gynecologic malignancies reported at a tertiary care center in India over the past decade: comparative evaluation with international data. Indian J Cancer. 2012;49(3):298–302.CrossRefPubMedGoogle Scholar
  3. 3.
    zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342–50.CrossRefPubMedGoogle Scholar
  4. 4.
    Chaudhary AK et al. Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview. Mutat Res. 2013;753(1):7–23.CrossRefPubMedGoogle Scholar
  5. 5.
    Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res: Off J Am Assoc Cancer Res. 2000;6(12):4823–30.Google Scholar
  6. 6.
    Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem. 2001;276(10):7549–58.CrossRefPubMedGoogle Scholar
  7. 7.
    Sheu BC et al. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 2001;61(1):237–42.PubMedGoogle Scholar
  8. 8.
    Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol. 2007;211(1):19–26.CrossRefPubMedGoogle Scholar
  9. 9.
    Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. Faseb J. 1999;13(8):781–92.PubMedGoogle Scholar
  10. 10.
    Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002;2(9):657–72.CrossRefPubMedGoogle Scholar
  11. 11.
    Chaudhary AK et al. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. J Biomed Sci. 2010;17:10.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. Febs J. 2011;278(1):16–27.CrossRefPubMedGoogle Scholar
  13. 13.
    Chattopadhyay K. A comprehensive review on host genetic susceptibility to human papillomavirus infection and progression to cervical cancer. Indian J Hum Genet. 2011;17(3):132–44.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Calhoun ES et al. Host genetic polymorphism analysis in cervical cancer. Clin Chem. 2002;48(8):1218–24.PubMedGoogle Scholar
  15. 15.
    Nunobiki O et al. Genetic polymorphism of cancer susceptibility genes and HPV infection in cervical carcinogenesis. Patholog Res Int. 2011;2011:364069.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Kaewprag J et al. HPV16 oncoproteins promote cervical cancer invasiveness by upregulating specific matrix metalloproteinases. PLoS One. 2013;8(8):e71611.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Libra M et al. Uterine cervical carcinoma: role of matrix metalloproteinases (review). Int J Oncol. 2009;34(4):897–903.CrossRefPubMedGoogle Scholar
  18. 18.
    Baltazar-Rodriguez LM et al. Polymorphism in the matrix metalloproteinase-2 gene promoter is associated with cervical neoplasm risk in Mexican women. Biochem Genet. 2008;46(3-4):137–44.CrossRefPubMedGoogle Scholar
  19. 19.
    Shastry BS. SNP alleles in human disease and evolution. J Hum Genet. 2002;47(11):561–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Qin H, Sun Y, Benveniste EN. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem. 1999;274(41):29130–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 2000;19(7):623–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Singh N et al. Downregulation of tumor suppressor gene PML in uterine cervical carcinogenesis: impact of human papillomavirus infection (HPV). Gynecol Oncol. 2012;128(3):420–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Chabra S et al. Solid lipid nanoparticles regulate functional assortment of mouse mesenchymal stem cells. J Stem Cells Regen Med. 2011;7(2):75–9.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Ye S et al. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 2001;29(17):E88–8.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kubben FJ et al. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer. 2006;95(6):744–51.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Das P et al. HPV genotyping and site of viral integration in cervical cancers in Indian women. PLoS One. 2012;7(7):e41012.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Parkin DM et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.CrossRefPubMedGoogle Scholar
  28. 28.
    Dunne EF et al. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis. 2006;194(8):1044–57.CrossRefPubMedGoogle Scholar
  29. 29.
    Hussain S et al. Transcription factor AP-1 in esophageal squamous cell carcinoma: alterations in activity and expression during human papillomavirus infection. BMC Cancer. 2009;9:329.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Singh N. et al. Implication of high risk Human papillomavirus HR-HPV infection in prostate cancer in Indian population- a pioneering case-control analysis. Sci Rep. 2015;5.Google Scholar
  31. 31.
    Guo Y, Jamison DC. The distribution of SNPs in human gene regulatory regions. BMC Genomics. 2005;6:140.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Zhang L-Y, Ren K-W. Meta-analysis of MMP2–1306T allele as a protective factor in digestive cancer. Arch Med Res. 2011;42:239–43.CrossRefPubMedGoogle Scholar
  33. 33.
    Yu C et al. Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res. 2002;62(22):6430–3.PubMedGoogle Scholar
  34. 34.
    Garzetti GG et al. The role of human papillomavirus DNAs in cervical carcinoma and risk of lymph node metastasis: association with 72-kilodalton metalloproteinase immunostaining. Cancer. 1998;82(5):886–92.CrossRefPubMedGoogle Scholar
  35. 35.
    Sato T et al. Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol. 2004;92(1):47–56.CrossRefPubMedGoogle Scholar
  36. 36.
    Brummer O et al. MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformation--an immunohistochemical study. Gynecol Oncol. 2002;84(2):222–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Tamakoshi K et al. Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form. Cancer. 1995;76(12):2565–71.CrossRefPubMedGoogle Scholar
  38. 38.
    Srivastava P et al. Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in North India. Arch Med Res. 2012;43(2):117–24.CrossRefPubMedGoogle Scholar
  39. 39.
    Dos Reis ST et al. Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer. J Urol. 2009;181(5):2320–5.CrossRefPubMedGoogle Scholar
  40. 40.
    Luizon MR, de Almeida Belo V. Matrix metalloproteinase (MMP)-2 and MMP-9 polymorphisms and haplotypes as disease biomarkers. Biomarkers. 2012;17(3):286–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Wu LM et al. MMP2 promoter polymorphism (C-1306T) and risk of recurrence in patients with hepatocellular carcinoma after transplantation. Clin Genet. 2008;73(3):273–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Xu E et al. Association of matrix metalloproteinase-2 and -9 promoter polymorphisms with colorectal cancer in Chinese. Mol Carcinog. 2007;46(11):924–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Zhou P et al. Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2011;127(3):813–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Chaudhary AK et al. Role of functional polymorphism of matrix metalloproteinase-2 (-1306 C/T and -168 G/T) and MMP-9 (-1562 C/T) promoter in oral submucous fibrosis and head and neck squamous cell carcinoma in an Indian population. Biomarkers. 2011;16(7):577–86.CrossRefPubMedGoogle Scholar
  45. 45.
    Hill AV. Immunogenetics and genomics. Lancet. 2001;357(9273):2037–41.CrossRefPubMedGoogle Scholar
  46. 46.
    Smola-Hess S et al. Expression of membrane type 1 matrix metalloproteinase in papillomavirus-positive cells: role of the human papillomavirus (HPV) 16 and HPV8 E7 gene products. J Gen Virol. 2005;86(Pt 5):1291–6.CrossRefPubMedGoogle Scholar
  47. 47.
    Asha Nair S et al. Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix. J Cancer Res Clin Oncol. 2003;129(2):123–31.PubMedGoogle Scholar
  48. 48.
    Nuovo GJ. In situ detection of PCR-amplified metalloproteinase cDNAs, their inhibitors and human papillomavirus transcripts in cervical carcinoma cell lines. Int J Cancer. 1997;71(6):1056–60.CrossRefPubMedGoogle Scholar
  49. 49.
    Chattopadhyay N et al. Human cervical tumor cell (SiHa) surface alphavbeta3 integrin receptor has associated matrix metalloproteinase (MMP-2) activity. J Cancer Res Clin Oncol. 2001;127(11):653–8.CrossRefPubMedGoogle Scholar
  50. 50.
    Shiau MY et al. Human papillomavirus up-regulates MMP-2 and MMP-9 expression and activity by inducing interleukin-8 in lung adenocarcinomas. PLoS One. 2013;8(1):e54423.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Sobti RC et al. Overexpression of STAT3 in HPV-mediated cervical cancer in a North Indian population. Mol Cell Biochem. 2009.Google Scholar
  52. 52.
    Xie TX et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene. 2004;23(20):3550–60.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Systems Biology Research Centre—Tumor biology, School of Life SciencesUniversity of SkövdeSkövdeSweden
  2. 2.Department of BiotechnologyPanjab UniversityChandigarhIndia
  3. 3.Division of Molecular OncologyInstitute of Cytology and Preventive Oncology (ICMR)NoidaIndia
  4. 4.Division of Molecular Genetics and BiochemistryInstitute of Cytology and Preventive Oncology (ICMR)NoidaIndia
  5. 5.Department of Obstetrics and GynecologyPost Graduate Institute of Medical Education and ResearchChandigarhIndia
  6. 6.Department of Cytology & Gynae. PathologyPost Graduate Institute of Medical Education and ResearchChandigarhIndia
  7. 7.Vice Chancellor BBA (Central) UniversityLucknowIndia

Personalised recommendations